Indian pharma stocks slide as Trump outlines tariffs of up to 200% on generic drugs
Aurobindo Pharma, Sun Pharma, Cipla and peers fell after a proposed US tariff roadmap put imported generics at risk. A two-year zero-duty window offers Indian exporters time to build US capacity or partnerships before duties are slated to rise to 100% in 2028 and 200% in 2029.
Indian pharma stocks fell after Trump proposed phased US tariffs on imported generic drugs. The two-year duty-free window gives exporters time to localise production or build US manufacturing partnerships, but eventual 100% and 200% tariffs threaten India-based supply economics.
Why this matters
No related recent Aurobindo Pharma signals were provided. The proposed tariff roadmap introduces a US-market risk for Indian generic-drug exporters and raises the urgency of local capacity or partnerships.
Retail-company signals are accelerating: +986700% QoQ.